Latasha Koszewnik, DPM
Foot & Ankle Surgery · Morgan Hill, CANPI 1417103961
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 34.3% of the total. That places this record below the midpoint for foot & ankle surgery clinicians in CA, where the typical reported total is $2,067.
Across 24 payments — averaging $22.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$188
- Amgen$146
- Lilly USA, LLC$84
- AbbVie$52
- Exact Sciences$28
- Cipher Pharmaceuticals US LLC$26
- plus $24 from 1 others
What the payments were for
- Food & beverage$547100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $188 |
| Amgen | 7 | $146 |
| Lilly USA, LLC | 4 | $84 |
| AbbVie | 2 | $52 |
| Exact Sciences | 1 | $28 |
| Cipher Pharmaceuticals US LLC | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 1 | $24 |
How this compares
$547 in reported general payments places this provider in the 25th percentile of 1,126 foot & ankle surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clotrimazole | 16 | $160 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Morgan Hill
- Eric GizaSacramento$3.6M
- Thomas HarrisPasadena$3M
- Thomas ChangSanta Rosa$2M
- Michael CoughlinSan Francisco$1.6M
- Vladimir ZeetserEncino$677K
- Jason NowakRedding$526K
- Candice BradyCamarillo$462K
- Andrew HsuOrange$456K
- Eric TanLos Angeles$447K
- Joseph ParkBurbank$387K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.